After tense standoff, AstraZeneca and Daiichi's Enhertu turned away by NICE on pricing grounds

After a prior skirmish over tax policy in England, AstraZeneca is now butting heads with officials in the country over innovative drug access.

In a decision released Monday, England’s National Institute for Health and Care Excellence (NICE) said it’s “disappointed” that AstraZeneca and its antibody-drug conjugate partner Daiichi Sankyo won’t “offer a fair price” on Enhertu to treat advanced HER2-low breast cancer.